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Abstract 25 
Interactions in the airway ecology of cystic fibrosis may alter organism persistence and clinical outcomes. 26 
Better understanding of such interactions could guide clinical decisions. We fitted logistic regression models 27 
using generalized estimating equations to longitudinal two-year patient cohorts in the Cystic Fibrosis 28 
Foundation Patient Registry, 2003-2011 to study associations between airway organisms present in each 29 
calendar year and their presence in the subsequent year. Models were adjusted for clinical characteristics and 30 
multiple observations per patient and tested for sensitivity to cystic fibrosis-specific treatments. The study 31 
included 28,042 patients aged six and older from 257 accredited US Care Centers and Affiliates with sputum 32 
cultures for at least two consecutive years for methicillin-sensitive Staphylococcus aureus, methicillin-resistant 33 
S aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, Stenotrophomonas maltophilia, 34 
Achromobacter xylosoxidans, and Candida and Aspergillus species. We analyzed 99.8% of 538,458 sputum 35 
cultures from the patients during the study period. Methicillin-sensitive S aureus was negatively associated with 36 
subsequent P aeruginosa. P aeruginosa was negatively associated with subsequent B cepacia complex, A 37 
xylosoxidans, and S maltophilia. B cepacia complex was negatively associated with future presence of all 38 
studied bacteria and Aspergillus species. P aeruginosa, B cepacia complex and S maltophilia were each 39 
reciprocally and positively associated with Aspergillus species. Independent of patient characteristics, studied 40 
organisms interact and alter outcomes of treatment decisions, sometimes in unexpected ways. By inhibiting P 41 
aeruginosa, methicillin-sensitive S aureus may delay lung disease progression. P aeruginosa and B cepacia 42 
complex may inhibit other organisms by decreasing airway biodiversity, potentially worsening lung disease. 43 
 44 
Introduction 45 
In the United States, Cystic Fibrosis (CF) affects roughly 30,000 people, reducing life expectancy by more than 46 
50% (1). Progressive pulmonary disease, marked by recurrent exacerbations, bacterial infection and declining 47 
lung function, drives morbidity and mortality (2–5). Studies of the CF lung reveal a diverse microbiology with 48 
methicillin-sensitive Staphylococcus aureus (MSSA) and Pseudomonas aeruginosa being the two most 49 
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commonly isolated organisms from the airway (1, 2). Opportunistic organisms including Burkholderia cepacia 50 
complex, Stenotrophomonas maltophilia, Achromobacter xylosoxidans, non-tuberculous Mycobacteria and 51 
fungal organisms commonly colonize and infect patients with CF. 52 
 The presence of different organisms alters long term outcomes of patients with CF. MSSA appears to 53 
enhance survival while B cepacia complex may presage catastrophic decline in health (6, 7). Acquisition of 54 
MRSA and P aeruginosa are associated with accelerated lung disease (8–12). Published cross-sectional data 55 
from the CF Foundation Patient Registry (CFFPR) show that dominant airway infections differ with age (1). 56 
MSSA most commonly infects pediatric patients, while P aeruginosa infection increases with age and 57 
commonly dominates the bacterial community in adult patients (13). Without clear understanding of the 58 
underlying microbial interactions, efforts to prevent, treat or eradicate specific organisms such as P aeruginosa 59 
may produce unexpected and undesirable outcomes. A double-blinded randomized controlled study in 2002 60 
showed that prophylactic treatment of MSSA with cephalexin in infants and young children with CF led to 61 
earlier colonization with P aeruginosa (14). Prophylaxis with ciprofloxacin had no effects on preventing 62 
infection with P aeruginosa (15). Similarly, eradication therapy for P aeruginosa increased infection with S 63 
maltophilia (15). 64 
 While antibiotic therapy may play a role, existing infections themselves appear to alter the rest of the 65 
microbiota (7, 16–19) and may thus alter clinical disease course. In vitro and non-human animal models show 66 
evidence of interspecies interaction between P aeruginosa and other pathogens including MSSA and B 67 
cenocepacia. Mathematical models of disease progression explore potential airway interactions between P 68 
aeruginosa, MSSA and Burkholderia species; results from these models are consistent with observational data 69 
in CF (1) and illustrate the potential impact of managing these organisms (7). 70 
 In this study, we focus on eight common CF airway pathogens and show how the presence of each in a 71 
given study year is associated with observed infections in the following year. By improving our understanding 72 
of interactions between organisms, we seek to enhance understanding of the underlying mechanisms of 73 
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changing airway microbial ecology which may help us anticipate the impacts of changing practice on clinical 74 
outcomes. 75 
 76 
Methods 77 
Study Design and Data 78 
We analyzed data from the CFFPR, 2003–2011, which contains prospectively collected patient data from 257 79 
US CF Foundation accredited care centers and affiliated programs. Data were gathered according to a defined 80 
protocol after obtaining written consent from adult patients or parental consent with assent from minors. The 81 
data include patient demographics, clinical measurements of CF disease, treatment information, number of 82 
clinic visits, and culture results from routine quarterly and acute illness samples. These data were monitored to 83 
confirm fidelity to medical charts (20). 84 
 We obtained approval from the University of Utah Investigational Review Board (IRB) for the 85 
performance of this study with a waiver for informed consent and approval from the Data Use Committee of the 86 
US CF Foundation for access to and use of the CF Foundation Patient Registry. We participate in data collection 87 
after written informed consent for the CF Foundation Patient Registry with separate approval from the IRB. 88 
  89 
Study population and definitions 90 
Our study cohort included all CFFPR subjects who had at least two consecutive years of data between 2003 and 91 
2011. Since 2003, the CFFPR records each culture result separately for every patient; previously, the CFFPR 92 
reported only a single annualized result per year thus guiding our study period selection. Patients younger than 93 
six years were excluded because they cannot reliably perform pulmonary function testing and usually do not 94 
produce sputum. We used sputum culture results to determine presence of infection. The CFFPR records 95 
organisms as present or absent for each culture and records the number of cultures obtained each given year. 96 
Presence of infection with a particular organism within a given calendar year was defined as at least one 97 
positive culture for that organism within that year. We focused on eight common infections, for which the 98 
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CFFPR contains sufficient data for analysis: MSSA, methicillin resistant S aureus (MRSA), B cepacia complex, 99 
P aeruginosa, S maltophilia, A xylosoxidans, Candida species and Aspergillus species. We identified and 100 
adjusted for the following patient characteristics as potential confounders in statistical models: age, age at 101 
diagnosis of CF, sex, CF-related diabetes, pancreatic sufficiency, weight-for-age z-score, percent predicted 102 
forced expiratory volume in one second (FEV1%), and acute pulmonary exacerbations (APE). Most of these 103 
characteristics were previously found to predict 5-year survival (6). We defined patients as diabetic in a given 104 
year if the condition was present at any time during that year. We defined patients as pancreatic sufficient in a 105 
given year if they were noted to be sufficient for all encounters and did not use pancreatic enzymes during that 106 
year. For sensitivity analyses to determine the effect of adjustment of associations for different interventions, we 107 
used treatment data on oral azithromycin, inhaled aztreonam, tobramycin, recombinant human DNase (DNase), 108 
and hypertonic saline, days per year of therapy with home intravenous (IV) antibiotics, hospitalization days for 109 
pulmonary exacerbation treatment, and lung transplantation. 110 
 111 
Statistical Analysis 112 
We fitted cross-sectional univariable logistic regression models (21) with presence of each organism in a given 113 
year as the outcome and each other organism studied as an individual explanatory variable. Cross-sectional 114 
multivariable models were then fitted with presence of each organism as the outcome and with all other 115 
organisms as explanatory variables with and without additional adjustment for clinical characteristics. These 116 
models were fitted separately in each calendar year, 2003-2011. We fitted similar multivariable logistic models 117 
relating organisms in each year t to presence of each organism in year t+1, where t=2003-2010, with and 118 
without additional adjustment for clinical characteristics. Finally, we fitted a single combined model across all 119 
observation years for each patient using generalized estimating equations with an independence working 120 
correlation matrix. This model uses multiple observations per individual across the study years. Using the 121 
combined model increases the power of our analysis and reduces the size of confidence intervals (22, 23). It 122 
makes the assumption that the associations between organisms from one year to the next are the same across the 123 
 o
n
 M
ay 22, 2018 by LO
NDO
N SCHO
O
L O
F HYG
IENE & TRO
PICAL M
ED
http://jcm.asm.org/
D
ow
nloaded from
 
Page 6 
calendar years. See the Online Supplement for detailed methods regarding the individual steps to fitting the 124 
combined model. Sensitivity analyses examined the impact of adjusting for treatments used. All analyses were 125 
performed using the R statistical system (24). 126 
 127 
Results 128 
Participants 129 
We found 28,042 patients aged six years or older in the CFFPR from 257 care centers and affiliated programs 130 
accredited by the US CF Foundation between January 1, 2003 and December 31, 2011 with at least two 131 
consecutive years of culture data (Table 1). These patients had a total of 538,458 sets of sputum culture results 132 
of which 537,396 (99.8%) were included in our analysis (Figure 1). Culture results were excluded only for lack 133 
of same-patient cultures in contiguous years. From 2003 to 2011, the median cross-sectional age of patients 134 
increased from 16.6 to 19.1 (Table 1). CF-related diabetes prevalence nearly doubled over this time period from 135 
9.62% to 17.5%. A minority of patients were pancreatic sufficient; this increased between 2003 and 2011 from 136 
6.53% to 11.2%.  There were marginal changes in the median FEV1% and mean number of APE during the 137 
study period. The changes in pediatric and adult groups were similar (Tables S1 and S2). 138 
 139 
Infection Prevalence 140 
There were changes in percentages of patients with positive cultures for the eight most common infections 141 
recorded in the CFFPR between 2003 and 2011 (Table 1, Figure 1, and Tables S1 and S2). Percentages of 142 
patients infected by MRSA and Candida species more than doubled, and percentages with S maltophilia, A 143 
xylosoxidans, and Aspergillus species also increased. Between 2003 and 2011, there were statistically 144 
significant small decreases in percentages of patients infected by MSSA (50.2% to 49.2%) and P aeruginosa 145 
(63.8% to 57.3%). 146 
 147 
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Cross Sectional Associations between Airway Infections 148 
Figure 2 shows estimated odds ratios from multivariable logistic regression models fitted in each year 2003-149 
2011 with each organism as an outcome and the set of all other organisms as explanatory variables, with and 150 
without adjustment for clinical variables and number of cultures. Estimates were remarkably consistent across 151 
calendar years. P aeruginosa infection was negatively associated with MSSA, B cepacia complex, S maltophilia 152 
and A xylosoxidans and was positively associated with Aspergillus species infections for every study year with 153 
or without adjustment for the presence of other organisms (Figure 2A, D, E, F and H, respectively). P 154 
aeruginosa and B cepacia complex were negatively associated in every study year with or without adjustment 155 
for other organisms, and additional adjustments for clinical characteristics intensified these associations (Figure 156 
2B and D). After adjustment for other organisms and with or without adjustment for clinical characteristics, P 157 
aeruginosa infection was negatively associated with MRSA for each year from 2004 through 2011 (Figure 2C). 158 
A xylosoxidans infections were associated with B cepacia complex infections every study year with large 159 
negative coefficients suggesting that co-infections are uncommon (Figure 2D). In contrast, S maltophilia was 160 
associated with Aspergillus species infections every year with large positive coefficients suggesting that co-161 
infections are common (Figure 2H). Odds ratios from logistic regression models examining univariable, 162 
unadjusted associations between organisms are similar to the full adjusted results (Figure S1). 163 
 164 
Associations between Present and Future Airway Infections 165 
Figure 3 shows the estimated odds ratios from multivariable models for the associations of microbial infection 166 
status for each of the years 2004 through 2011 (years t+1) with infections in the previous year where t=2003-167 
2010, by year (21). Associations were similar for every two year period examined, with some variation in 168 
degree of statistical significance for individual relationships. 169 
 For each organism, the predictor most strongly associated with its presence in year t+1 was presence of 170 
the same organism in year t (Figure S2). MSSA, B cepacia complex, S maltophilia and A xylosoxidans in year t 171 
were all negatively associated with P aeruginosa in each year t+1 (Figure 3B). Candida or Aspergillus species 172 
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were not typically associated with subsequent P aeruginosa (Figure 3B). Other organisms besides MSSA and B 173 
cepacia complex in each year t were infrequently associated with MRSA in each year t+1. MSSA in three years 174 
t (2005, 2008, and 2010) and B cepacia complex infections in two years t (2005 and 2007) had potentially 175 
significant negative statistical and clinical associations with MRSA (Figure 3C). Adjustment for clinical 176 
variables did not substantially change the estimates or their statistical significance (Figure 3). 177 
 When using all observations simultaneously in the combined model, the relationships between an 178 
organism seen in year t with a different organism in year t+1 (Figure 4, Tables S3 and S4) were similar to all 179 
relationships seen in multivariable logistic regression models for each of the two-year models reported above 180 
but with much narrower confidence intervals (Figure 3).  Adjustment for clinical characteristics produced 181 
similar results (Figure 4, Tables S3 and S4). These models again showed that organism presence in year t was 182 
most strongly associated with the same organisms in year t+1 (Figure S3). Sensitivity analyses in which we 183 
additionally adjusted, one at a time, for clinical treatments given in year t showed that associations were not 184 
substantially altered. 185 
 186 
Missingness of Data 187 
Our study population included patients who had two consecutive years of culture data at least once between 188 
2003 and 2011 (Table 1).  We analyzed cohorts and patients for missing data. The proportion of patients 189 
excluded for any two-year cohort ranged from 4.6% to 7.5% (Table S5). There were small but statistically 190 
significant differences between study patients and patients with missing data. Excluded patients tended to be 191 
older, with higher prevalence of diabetes and slightly decreased lung function, however, they also appeared in 192 
other ways to be healthier, with better nutritional status, fewer APE and higher rates of pancreatic sufficiency 193 
(Tables S6, S7 and S8). 194 
 195 
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Discussion 196 
Our study of microbiology in the human airway reveals microbial interactions that may alter therapeutic 197 
responses in individuals with CF. Current organisms change the odds of finding other microbes concurrently 198 
and in the future. Among studied organisms, the likelihood of retention is highest for P aeruginosa, MRSA, and 199 
especially B cepacia complex, the most clinically pathogenic organisms. In contrast, MSSA, the only organism 200 
associated with increased 5-year survival in CF (6), is the least likely to persist from one year to the next. The 201 
presence of P aeruginosa, MRSA and B cepacia complex all reduce the likelihood of culturing MSSA in future 202 
years thus likely reducing patient survival. 203 
 Prior studies of small groups of patients using molecular analysis methods show that a patient is more 204 
likely to retain current infections than lose them (25, 26). The chronicity of specific infections (27), their 205 
interactions with human host defenses and their clinical outcomes are previously studied (28). Microbial 206 
species-to-species interactions among pathogens similar to those found in the CF airway have been studied in 207 
various in vitro and non-human in vivo model systems (17, 18, 29–37), and the clinical effects of the 208 
combination of P aeruginosa and MSSA have been explored (38), but interspecies microbial interactions in the 209 
CF airway are minimally explored, and recent calls to expand this knowledge base remain outstanding (16, 39). 210 
 Our study answers this call quantitatively by precisely showing that current infections alter the odds of 211 
finding other organisms in subsequent years. Our study uses an approximately thousand-fold or larger group of 212 
patients than prior studies examining organism persistence alone, thus providing the additional power necessary 213 
to explore interspecies interactions with confidence. We demonstrate these associations in extensive univariable 214 
and multivariable models (adjusted for other infections and clinical variables), and we demonstrate a lack of 215 
sensitivity to varying clinical status and all common treatments. The stability of the results despite variability in 216 
clinical states and prescribing of common treatments underscores the need to understand potential effects of 217 
persistent microbial interactions to avoid undesirable clinical outcomes. 218 
 The strongest association between organisms was the negative one between MSSA and P aeruginosa 219 
between years t and t+1 in both directions (Figures 2, 3 and 4).  All associations were independent of the 220 
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presence of other organisms (Figure 4 and Table S3) and the severity of clinical characteristics (Figure 4 and 221 
Table S4), and they were insensitive to the use of multiple CF-specific therapies including chronic and acute 222 
antibiotic treatments. MSSA may limit acquisition and reduce persistence of P aeruginosa infection in some 223 
patients, and P aeruginosa may supplant MSSA infection in others (1). These observations are consistent with 224 
previous findings that elimination of MSSA leads to more rapid infection with P aeruginosa (14). 225 
 The two most harmful bacterial pathogens in CF, P aeruginosa and B cepacia complex, are also the 226 
organisms in our study that were associated with the greatest number of other studied infections (Figure 4). The 227 
presence of either P aeruginosa or B cepacia complex was associated with lower odds of future MSSA, S 228 
maltophilia, and A xylosoxidans. B cepacia complex was additionally associated with lower odds for concurrent 229 
(Figure 2C, turquoise cluster) and subsequent MRSA (Figure 4C). By limiting acquisition or persistence of 230 
other infections, P aeruginosa and B cepacia complex may decrease microbial diversity. Loss of diversity in CF 231 
airway ecology is linked with worsening lung disease, an observation consistent with the increased 232 
pathogenicity of P aeruginosa and B cepacia complex in CF (13, 19). 233 
 Our study shows that S maltophilia and A xylosoxidans each had less influence on each other and the 234 
other six organisms in our study than did P aeruginosa or B cepacia complex (Figures 2, 3 and 4). The 235 
decreased impact on diversity may help explain, for example, why S maltophilia seems less pathogenic in CF 236 
(40). Our study supports previous findings that intermittent infection with S maltophilia does not substantially 237 
affect progression of lung disease or survival (41–43). 238 
 Aspergillus and Candida species are the most commonly cultured fungal infections in the CF airway 239 
(44). The extent and nature of interaction between fungal and bacterial infections in the CF airway is unclear. 240 
Previous in vitro and non-human in vivo model based research demonstrated inhibition of biofilm formation in 241 
both Candida and Aspergillus by P aeruginosa (29, 30, 37). Our study based on clinical observation suggests 242 
that P aeruginosa and S maltophilia infections are associated with higher rather than lower odds of concurrent 243 
and subsequent Aspergillus infection (Figures 2H, S1, 3H and 4H). MRSA and S maltophilia were associated 244 
with slightly higher odds of subsequent Candida infection (Figure 4G). Only B cepacia complex was associated 245 
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with lower odds for a future fungal infection, and only for Aspergillus species (Figure 4G). The discrepancies 246 
between our observations and those from non-human models of P aeruginosa and Aspergillus interactions (29, 247 
30, 37) may merely reflect differences between model system and human airway conditions but may indicate 248 
the presence of important differences in microbial virulence (45). Evidence of interspecies interactions may help 249 
explain why approximately a third of efforts to eradicate pathogens from the CF airway fail (46, 47): perhaps a 250 
non-targeted concurrent infection promotes persistence of a target organism. The clinical impacts of these 251 
associations remain uncertain but their potential for altering disease course and outcomes invites further study. 252 
 Our findings suggest that microbial interaction exists in the airways of patients with CF regardless of 253 
treatments and events that may modify the presence of microbes. Potential interaction mechanisms may be 254 
considered. First, microbes produce antimicrobial agents (31). The strength of associations between MSSA, P 255 
aeruginosa and B cepacia complex (Figure 4A, B and D) are consistent with prior findings that these organisms 256 
produce novel antimicrobials (48–52). Second, organisms may compete for airway resources such as iron (32, 257 
53). Third, organisms may interact with human host defenses or with each other to modify interactions with yet 258 
other organisms (35, 54).  Finally, our confirmation of the consistency and strength of microbial interactions 259 
regardless of mechanism suggests additional areas for investigation of clinical impacts. Expanded knowledge of 260 
microbial interactions may explain unexpected outcomes of antimicrobial therapy (14, 15), better delineate the 261 
pathogenesis of pulmonary exacerbations in CF that punctuate and accelerate the course of disease (55), and 262 
improve predictions of long term outcomes critical to the well-being of patients (6, 7, 56). 263 
 264 
Limitations 265 
First, there may be unrecorded treatment decisions that affect airway ecology. However prior studies show that 266 
short-course antibiotic therapy only transiently affects a CF patient’s individual microbiota (26, 57). Moreover, 267 
our analysis showed that adjustment for various treatments did not materially alter results. Second, we were 268 
limited to studying the eight organisms for which there are sufficient culture data present in the CFFPR. This 269 
excluded direct study of many CF airway organisms that are infrequently present, under reported, not collected 270 
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during the study period (such as non-tuberculous Mycobacteria) or only identifiable by non-culture methods 271 
(58). The use of culture data is subject to variable rates, by organism, of false positive or negative results; 272 
however, similar difficulties affect recovery of organisms by non-culture methods (58). Furthermore, results 273 
from conventional aerobic sputum cultures are the data that drive clinical decisions in treating patients with CF, 274 
are correlated with results from culture independent methods for identifying the common aerobic CF infections 275 
analyzed in our study, especially P aeruginosa (26, 58), and provide the basis of prior reports showing 276 
associations between organisms and survival outcomes (6, 9). Lastly, there are potential biases from 277 
missingness of data that prevented inclusion of some patients in the analysis. However, the proportion of 278 
patients with missingness was quite low (Tables S6, S7 and S8). The patients in the CFFPR during the study 279 
period who never had sufficient data for inclusion accounted for 0.2% to 0.9% of all CFFPR patients during 280 
each year of the study period (Tables S7 and S8). There may also be data in the CFFPR that were partially 281 
available for adjustment of our models but which we excluded from the analysis for various reasons. For 282 
example, we did not use genotype data because it was unavailable for a large proportion of the patients studied 283 
and because it is less successful as a predictor of long term clinical outcomes compared to clinical phenotype 284 
variables such as we previously used to predict 5-year survival outcomes (6). 285 
 286 
Conclusions 287 
This study helps clinicians understand how current microbiology may play a role in shaping the overall 288 
subsequent microbiology of the CF airway. Mechanistic studies are needed to understand specifically how 289 
MSSA may limit infection with P aeruginosa and how P aeruginosa and B cepacia complex may limit co-290 
infecting organisms. Such understanding has the potential to influence strategic decisions in CF clinical care. 291 
While a bacterial pathogen found in an otherwise healthy host is often met with an attempt at eradication, this 292 
strategy in CF may be defeated by interspecies interactions that promote persistence of multiple species and 293 
have unintended consequences even when seemingly successful. Eliminating specific infections within the 294 
diverse CF airway ecology may disrupt a delicate balance and accelerate the time to infection of more 295 
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pathogenic organisms. Determining the potential influence of each organism on the CF microbiome may help 296 
clinicians understand the extended impact of modifying a patient’s airway ecology and ultimately improve 297 
patient survival. 298 
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Figure Legends 360 
Figure 1. Prevalence of positive cultures for studied infections, 2003-2011. Eight curves show the changing 361 
prevalence of the organisms studied for the patients in the CFFPR for each of the years 2003 through 2011 able 362 
to produce samples for microbiologic cultures. The figure is similar to prior figures showing the data in 363 
somewhat different ways (59). 364 
Figure 2. Adjusted cross-sectional associations between airway infections. Forest plots show the adjusted 365 
odds ratios (circles) and 99% confidence intervals (bars) of having a positive culture for each of the eight 366 
studied organisms within each study year comparing presence versus absence of a positive culture for each of 367 
the other seven organisms in the same year. The outcomes were (A) MSSA: methicillin sensitive 368 
Staphylococcus aureus, (B) PA: Pseudomonas aeruginosa, (C) MRSA: methicillin resistant S aureus, (D) BCC: 369 
Burkholderia cepacia complex, (E) SM: Stenotrophomonas maltophilia, (F) AX: Achromobacter xylosoxidans, 370 
(G) CS: Candida species, (H) AS: Aspergillus species. Purple results are from models adjusted by the presence 371 
of the remaining six other organisms. Turquoise results are from models additionally adjusted for clinical 372 
characteristics: age, sex, late diagnosis of CF, best FEV1% in each year, annual number of APE, pancreatic 373 
sufficiency and diabetes status and weight-for-age z-score. 374 
Figure 3. Adjusted associations between airway infections in years 2003-2010 with other organisms in 375 
subsequent years 2004-2011.  Forest plots show the odds ratio (circles) and 99% confidence intervals (bars) of 376 
having a positive culture in years t+1 for each of the eight studied organisms when each of the other organisms 377 
were present in respective years t where t=2003-2010. The outcomes from years t+1 were (A) MSSA: 378 
methicillin sensitive Staphylococcus aureus, (B) PA: Pseudomonas aeruginosa, (C) MRSA: methicillin resistant 379 
S aureus, (D) BCC: Burkholderia cepacia complex, (E) SM: Stenotrophomonas maltophilia, (F) AX: 380 
Achromobacter xylosoxidans, (G) CS: Candida species, (H) AS: Aspergillus species. Red results are from 381 
models adjusted by the presence of the remaining six organisms. Green results are from models additionally 382 
adjusted for clinical characteristics in years t: age, sex, late diagnosis of CF, best FEV1% in each year, annual 383 
number of APE, pancreatic sufficiency and diabetes status and weight-for-age z-score. 384 
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Figure 4. Adjusted associations between airway infections in year t with other organisms in year t+1. Each 385 
forest plot shows the odds ratios (circles) and 99% confidence intervals (bars) from the combined model 386 
utilizing the entire 2003-2011 CFFPR data set for each of the eight studied organisms in year t+1 when each of 387 
the other organisms were present in respective years t where t=2003-2010. The outcomes from years t+1 were 388 
(A) MSSA: methicillin sensitive Staphylococcus aureus, (B) PA: Pseudomonas aeruginosa, (C) MRSA: 389 
methicillin resistant S aureus, (D) BCC: Burkholderia cepacia complex, (E) SM: Stenotrophomonas 390 
maltophilia, (F) AX: Achromobacter xylosoxidans, (G) CS: Candida species, (H) AS: Aspergillus species. Red 391 
results are from models adjusted by the presence of the remaining six organisms. Green results are from models 392 
additionally adjusted for clinical characteristics for years t: age, sex, late diagnosis of CF, best FEV1% in each 393 
year, annual number of APE, pancreatic sufficiency and diabetes status and weight-for-age z-score.  394 
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Table 1. Selected Characteristics of Study Patients 1 
Patient 
Characteristics 
Year 
2003 2004 2005 2006 2007 2008 2009 2010 2011 
Number Enrolled 15626 16428 16933 17483 18305 18786 19384 19818 20534 
Number of 
culturesa 
42995 
(0.996) 
47516 
(0.999) 
51826 
(1.000) 
55922 
(0.999) 
61442 
(1.000) 
65319 
(1.000) 
68312 
(1.000) 
70294 
(0.999) 
74409 
(1.000) 
Cultures per 
Patientb 
2 (1 - 4) 2 (1 - 4) 3 (2 - 4) 3 (2 - 4) 3 (2 - 4) 3 (2 - 4) 3 (2 - 4) 3 (2 - 4) 3 (2 - 5) 
Ageb 16.6 (11.4 - 24.0) 
17.0 (11.7 - 
24.5) 
17.2 (11.8 - 
24.8) 
17.6 (12.0 - 
25.3) 
17.8 (12.1 - 
25.9) 
18.1 (12.2 - 
26.4) 
18.4 (12.4 - 
27.0) 
18.7 (12.5 - 
27.4) 
19.1 (12.7 - 
27.9) 
Femalec 7446 (47.7) 7811 (47.5) 8050 (47.5) 8319 (47.6) 8764 (47.9) 9060 (48.2) 9393 (48.5) 9618 (48.5) 9949 (48.5) 
Pancreatic 
Sufficiencyc 
1018 (6.53) 1198 (7.30) 1189 (7.03) 1365 (7.81) 1457 (7.96) 1654 (8.80) 1830 (9.44) 2419 (12.2) 2300 (11.2) 
Diabetesc 1503 (9.62) 1744 (10.6) 1919 (11.3) 2410 (13.8) 2664 (14.6) 2845 (15.1) 3022 (15.6) 3270 (16.5) 3601 (17.5) 
FEV1%b 81.0 (58.7 - 97.0) 
81.5 (59.2 - 
97.2) 
82.0 (59.6 - 
97.5) 
82.6 (60.2 - 
97.7) 
83.0 (60.4 - 
98.5) 
83.2 (60.7 - 
98.7) 
83.5 (60.7 - 
99.0) 
83.9 (61.3 - 
99.1) 
83.7 (61.3 - 
99.0) 
Acute Pulmonary 
Exacerbationsb 
0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 0 (0 - 1) 
Weight-for-Age 
z-scoreb 
-0.52 (-1.23 
- 0.18) 
-0.47 (-1.20 
- 0.21) 
-0.45 (-1.17 
- 0.22) 
-0.40 (-1.12 
- 0.25) 
-0.38 (-1.10 
- 0.27) 
-0.33 (-1.06 
- 0.30) 
-0.29 (-1.04 
- 0.33) 
-0.27 (-1.04 
- 0.35) 
-0.25 (-1.03 
- 0.36) 
MSSAc 7852 (50.2) 8292 (50.5) 8497 (50.2) 8704 (49.8) 9140 (49.9) 9299 (49.5) 9574 (49.4) 9759 (49.2) 10104 (49.2) 
P aeruginosac 9969 (63.8) 10469 (63.7) 10656 (62.9) 10729 (61.4) 11100 (60.6) 11123 (59.2) 11323 (58.4) 11482 (57.9) 11767 (57.3) 
MRSAc 2034 (13.0) 2642 (16.1) 3155 (18.6) 3588 (20.5) 4150 (22.7) 4576 (24.4) 5005 (25.8) 5514 (27.8) 5801 (28.3) 
Burkholderia 
Complexc 
584 (3.74) 580 (3.53) 622 (3.67) 607 (3.47) 622 (3.40) 618 (3.29) 619 (3.19) 697 (3.52) 756 (3.68) 
S maltophiliac 1868 (12.0) 2064 (12.6) 2243 (13.2) 2320 (13.3) 2440 (13.3) 2457 (13.1) 2616 (13.5) 2881 (14.5) 3010 (14.7) 
A xylosoxidansc 1028 (6.58) 1095 (6.67) 1166 (6.89) 1240 (7.09) 1236 (6.75) 1355 (7.21) 1343 (6.93) 1468 (7.41) 1501 (7.31) 
Candida species’ 1295 (8.29) 1177 (7.16) 1365 (8.06) 1370 (7.84) 1391 (7.60) 1609 (8.56) 1661 (8.57) 3129 (15.8) 3559 (17.3) 
Aspergillus 
speciesc 
2458 (15.7) 2677 (16.3) 2724 (16.1) 2913 (16.7) 2996 (16.4) 3190 (17.0) 3141 (16.2) 3409 (17.2) 3678 (17.9) 
a Number (fraction of cultures obtained from study participants with usable data) 
b Median (1st and 3rd quartiles) 
c Number of Patients (percent of enrolled patients) 
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